|
1
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yi M, Li A, Zhou L, Chu Q, Luo S and Wu K:
Immune signature-based risk stratification and prediction of immune
checkpoint inhibitor's efficacy for lung adenocarcinoma. Cancer
Immunol Immunother. 70:1705–1719. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Germain C, Gnjatic S, Tamzalit F,
Knockaert S, Remark R, Goc J, Lepelley A, Becht E, Katsahian S,
Bizouard G, et al: Presence of B cells in tertiary lymphoid
structures is associated with a protective immunity in patients
with lung cancer. Am J Respir Crit Care Med. 189:832–844. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nesbitt JC, Putnam JB Jr, Walsh GL, Roth
JA and Mountain CF: Survival in early-stage non-small cell lung
cancer. Ann Thorac Surg. 60:466–472. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen-Kiang S: Cell-cycle control of plasma
cell differentiation and tumorigenesis. Immunol Rev. 194:39–47.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
O'Connor BP, Gleeson MW, Noelle RJ and
Erickson LD: The rise and fall of long-lived humoral immunity:
Terminal differentiation of plasma cells in health and disease.
Immunol Rev. 194:61–76. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaudhary RK, Patil P, Ananthesh L,
Srinivasa MG, Mateti UV, Shetty V and Khanal P: Identification of
signature genes and drug candidates for primary plasma cell
leukemia: An integrated system biology approach. Comput Biol Med.
162:1070902023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lahiri A, Maji A, Potdar PD, Singh N,
Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer
immunotherapy: Progress, pitfalls, and promises. Mol Cancer.
22:402023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hao D, Han G, Sinjab A, Gomez-Bolanos LI,
Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, et al: The
single-cell immunogenomic landscape of B and plasma cells in
early-stage lung adenocarcinoma. Cancer Discov. 12:2626–2645. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hong M, Tao S, Zhang L, Diao LT, Huang X,
Huang S, Huang S, Xie SJ, Xiao ZD and Zhang H: RNA sequencing: New
technologies and applications in cancer research. J Hematol Oncol.
13:1662020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Suvà ML and Tirosh I: Single-Cell RNA
sequencing in cancer: Lessons learned and emerging challenges. Mol
Cell. 75:7–12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang G, Qiu M, Xing X, Zhou J, Yao H, Li
M, Yin R, Hou Y, Li Y, Pan S, et al: Lung cancer scRNA-seq and
lipidomics reveal aberrant lipid metabolism for early-stage
diagnosis. Sci Transl Med. 14:eabk27562022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu J, Fan Y, Xiong Y, Wang W, Chen J, Xia
Y, Lei J, Gong L, Sun S and Jiang T: Delineating the dynamic
evolution from preneoplasia to invasive lung adenocarcinoma by
integrating single-cell RNA sequencing and spatial transcriptomics.
Exp Mol Med. 54:2060–2076. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim N, Kim HK, Lee K, Hong Y, Cho JH, Choi
JW, Lee JI, Suh YL, Ku BM, Eum HH, et al: Single-cell RNA
sequencing demonstrates the molecular and cellular reprogramming of
metastatic lung adenocarcinoma. Nat Commun. 11:22852020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang J, Liu X, Huang Z, Wu C, Zhang F,
Han A, Stalin A, Lu S, Guo S, Huang J, et al: T cell-related
prognostic risk model and tumor immune environment modulation in
lung adenocarcinoma based on single-cell and bulk RNA sequencing.
Comput Biol Med. 152:1064602023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Wang S and Lang JH: Development
and validation of nomogram with tumor microenvironment-related
genes and clinical factors for predicting overall survival of
endometrial cancer. J Cancer. 12:3530–3538. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Colaprico A, Silva TC, Olsen C, Garofano
L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM,
Castiglioni I, et al: TCGAbiolinks: An R/Bioconductor package for
integrative analysis of TCGA data. Nucleic Acids Res. 44:e712016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeser D, Gruener RF and Huang RS:
OncoPredict: An R package for predicting in vivo or cancer patient
drug response and biomarkers from cell line screening data. Brief
Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Asamura H, Nishimura KK, Giroux DJ,
Chansky K, Hoering A, Rusch V and Rami-Porta R; Members of the
IASLC Staging and Prognostic Factors Committee and of the Advisory
Boards, and Participating Institutions, : IASLC lung cancer staging
project: The new database to inform revisions in the ninth edition
of the TNM classification of lung cancer. J Thorac Oncol.
18:564–575. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lei Y, Tang R, Xu J, Wang W, Zhang B, Liu
J, Yu X and Shi S: Applications of single-cell sequencing in cancer
research: Progress and perspectives. J Hematol Oncol. 14:912021.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wouters MCA and Nelson BH: Prognostic
significance of tumor-infiltrating B cells and plasma cells in
human cancer. Clin Cancer Res. 24:6125–6135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song P, Li W, Guo L, Ying J, Gao S and He
J: Identification and validation of a novel signature based on NK
cell marker genes to predict prognosis and immunotherapy response
in lung adenocarcinoma by integrated analysis of single-cell and
bulk RNA-sequencing. Front Immunol. 13:8507452022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vuong L, Kouverianou E, Rooney CM, McHugh
BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR,
Nilsson UJ, et al: An orally active galectin-3 antagonist inhibits
lung adenocarcinoma growth and augments response to PD-L1 blockade.
Cancer Res. 79:1480–1492. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen S, Chen J, Hua X, Sun Y, Cui R, Sha J
and Zhu X: The emerging role of XBP1 in cancer. Biomed
Pharmacother. 127:1100692020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhong Z, Wang J, Han Q, Lin H, Luo H, Guo
D, Jiang Y and Liu A: XBP1 impacts lung adenocarcinoma progression
by promoting plasma cell adaptation to the tumor microenvironment.
Front Genet. 13:9695362022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Glasauer A, Sena LA, Diebold LP, Mazar AP
and Chandel NS: Targeting SOD1 reduces experimental non-small-cell
lung cancer. J Clin Invest. 124:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Somwar R, Erdjument-Bromage H, Larsson E,
Shum D, Lockwood WW, Yang G, Sander C, Ouerfelli O, Tempst PJ,
Djaballah H and Varmus HE: Superoxide dismutase 1 (SOD1) is a
target for a small molecule identified in a screen for inhibitors
of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci
USA. 108:16375–16380. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Okazaki K, Anzawa H, Liu Z, Ota N,
Kitamura H, Onodera Y, Alam MM, Matsumaru D, Suzuki T, Katsuoka F,
et al: Enhancer remodeling promotes tumor-initiating activity in
NRF2-activated non-small cell lung cancers. Nat Commun.
11:59112020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lorenz J, Zahlten J, Pollok I, Lippmann J,
Scharf S, N'Guessan PD, Opitz B, Flieger A, Suttorp N, Hippenstiel
S and Schmeck B: Legionella pneumophila-induced IκBζ-dependent
expression of interleukin-6 in lung epithelium. Eur Respir J.
37:648–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan T, Li S, Xiao C, Tian H, Zheng Y, Liu
Y, Li C and He J: CCL20 promotes lung adenocarcinoma progression by
driving epithelial-mesenchymal transition. Int J Biol Sci.
18:4275–4288. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li J, Li J, Hao H, Lu F, Wang J, Ma M, Jia
B, Zhuo M, Wang J, Chi Y, et al: Secreted proteins MDK, WFDC2, and
CXCL14 as candidate biomarkers for early diagnosis of lung
adenocarcinoma. BMC Cancer. 23:1102023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J, Xiao X, Ou Y, Cao L, Guo M, Qi C,
Wang Z, Liu Y, Shuai Q, Wang H, et al: USP51/PD-L1/ITGB1-deployed
juxtacrine interaction plays a cell-intrinsic role in promoting
chemoresistant phenotypes in non-small cell lung cancer. Cancer
Commun (Lond). 43:765–787. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen KC, Hsu WH, Ho JY, Lin CW, Chu CY,
Kandaswami CC, Lee MT and Cheng CH: Flavonoids luteolin and
quercetin inhibit RPS19 and contributes to metastasis of cancer
cells through c-Myc reduction. J Food Drug Anal. 26:1180–1191.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Andersen MK, Rise K, Giskeødegård GF,
Richardsen E, Bertilsson H, Størkersen Ø, Bathen TF, Rye M and
Tessem MB: Integrative metabolic and transcriptomic profiling of
prostate cancer tissue containing reactive stroma. Sci Rep.
8:142692018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Anagnostou V, Smith KN, Forde PM, Niknafs
N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N,
et al: Evolution of neoantigen landscape during immune checkpoint
blockade in non-small cell lung cancer. Cancer Discov. 7:264–276.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Steels E, Paesmans M, Berghmans T, Branle
F, Lemaitre F, Mascaux C, Meert AP, Vallot F, Lafitte JJ and
Sculier JP: Role of p53 as a prognostic factor for survival in lung
cancer: A systematic review of the literature with a meta-analysis.
Eur Respir J. 18:705–719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seliger B and Quandt D: The expression,
function, and clinical relevance of B7 family members in cancer.
Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang
F, Yang D, Gao A, Lin W, Ma X and Sun Y: B7-H3 in combination with
regulatory T cell is associated with tumor progression in primary
human non-small cell lung cancer. Int J Clin Exp Pathol.
8:13987–13995. 2015.PubMed/NCBI
|
|
45
|
Aggarwal C, Prawira A, Antonia S, Rahma O,
Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, Zandberg D, et
al: Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab
and pembrolizumab in advanced solid tumors: Interim results from a
multicenter phase I/II trial. J Immunother Cancer. 10:e0044242022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
He D, Zhao XQ, Chen XG, Fang Y, Singh S,
Talele TT, Qiu HJ, Liang YJ, Wang XK, Zhang GQ, et al: BIRB796, the
inhibitor of p38 mitogen-activated protein kinase, enhances the
efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
PLoS One. 8:e541812013. View Article : Google Scholar : PubMed/NCBI
|
